Your Strongest Ally to Conquer Cancer

Phone: 505.842.8171

dotAfter Hours: 505.857.3877

dotPharmacy: 505.822.3911

Latest Cancer News

Ribociclib Offers ‘Paradigm Shift’ in Advanced Breast Cancer (10-26-2016)

The investigational drug ribociclib (formerly LEE011) when combined with Femera (letrozole) for the initial treatment of postmenopausal women with hormone-receptor positive (HR+) metastatic breast cancer leads to improved survival without cancer recurrence. The... Continue Reading

Keytruda Approved for First-Line Treatment of Select Patients with Advanced Non-Small Cell Lung Cancer (10-25-2016)

The US Food and Drug Administration (FDA) has approved Keytruda® (pembrolizumab) as a first-line treatment options for patients with metastatic non-small cell lung cancer (NSCLC) whose tumors express high levels of PD-L1 without EGFR or ALK mutations. PD-1... Continue Reading

Tecentriq® Improves NSCLC Survival Compared to Chemotherapy Regardless of PD-L1 Status (10-25-2016)

Tecentriq® (atezolizumab) improves the outcomes of individuals with advanced non-small cell lung cancer (NSCLC) according to the results of a pivotal clinical trial presented at the European Society of Medical Oncology (ESMO) 2016 Annual Meeting this... Continue Reading

Yervoy® Improves Overall Survival in Fully Resected Stage III Melanoma Patients (10-24-2016)

Results were presented during the 2016 European Society for Medical Oncology Congress demonstrating that Yervoy® (ipilimumab) compared to placebo improves survival in stage III melanoma patients who are at high risk of recurrence following complete surgical... Continue Reading

Tesaro Provides Real Benefit to Ovarian Cancer Patients (10-20-2016)

Patients with platinum-sensitive recurrent ovarian cancer showed significantly improved cancer-free survival with Tesaro (niraparib) in the first clinical trial directly comparing a poly(ADP)-ribose polymerase (PARP) inhibitor with chemotherapy. Tesaro... Continue Reading

Immunotherapy May Become New Standard of Care in Advanced Non-Small Cell Lung Cancer (10-19-2016)

Researchers presented full results of Keytruda® (pembrolizumab) and Opdivo® (nivolumab) in previously untreated advanced non-small cell lung cancer (NSCLC) at the European Society for Medical Oncology annual meeting in Copenhagen. An additional study... Continue Reading

The HPV Vaccine Prevents Lesions That Could Cause Cervical Cancer by 50 Percent (10-13-2016)

A recent report published online Sept. 29 in the journal JAMA Oncology suggests that the vaccine against human papillomavirus (HPV) infection, which doctors believe causes most cases of cervical cancer, is more effective than previously thought. Human... Continue Reading

HOVON Trial: Autologous Stem Cell Transplant Remains Superior to Novel Agents for Treatment of Multiple Myeloma (10-12-2016)

A large, comparative, phase III HOVON clinical trial recently confirmed that upfront autologous stem cell transplantation (ASCT) should still be the treatment of choice in younger patients with newly diagnosed multiple myeloma (MM). The findings of this... Continue Reading

Epacadostat Plus Keytruda® Appears Effective in Melanoma (10-11-2016)

The treatment combination consisting of epacadostat plus Keytruda® (pembrolizumab) appears effective in the treatment of advanced melanoma. Melanoma is a type of skin cancer that often starts in the form of a mole. If detected and treatable with surgery,... Continue Reading

Myeloproliferative Neoplasms Greatly Affect Patient Quality of Life (10-10-2016)

According to results from the myeloproliferative neoplasms (MPN) Landmark survey, MPN’s negatively affect the quality of life and overall health of patients even a year before their diagnosis. Myeloproliferative neoplasms (MPN) are a related group of... Continue Reading

FDA Warns Against Ovarian Cancer Screening Tests (10-6-2016)

According to the US Food and Drug Administration (FDA) doctors and their patients should not use certain ovarian cancer screening tests because of inaccurate results. Screening tests are designed to detect cancer in its earliest stages when it is most... Continue Reading

PET/CT Combined More Effective Than MRI in Monitoring Head and Neck Cancer Patients’ Response to Treatment (10-5-2016)

According to a recent study, combining PET/CT to monitor response to treatment in head and neck cancer patients appears more effective than MRI. Using PET/CT may better inform doctors whether treatment for head and neck cancer is working after just one... Continue Reading

Next Page »